La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Transcenta Holding Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Xueming Qian

Directeur général

CN¥5.6m

Rémunération totale

Pourcentage du salaire du PDG	20.3%
Durée du mandat du directeur général	12yrs
Propriété du PDG	12.7%
Durée moyenne d'occupation des postes de direction	2.8yrs
Durée moyenne du mandat des membres du conseil d'administration	3.1yrs

Mises à jour récentes de la gestion

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

Analyse de la rémunération des PDG

Comment la rémunération de Xueming Qian a-t-elle évolué par rapport aux bénéfices de Transcenta Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-CN¥359m
Mar 31 2024	n/a	n/a	-CN¥411m
Dec 31 2023	CN¥6m	CN¥1m	-CN¥463m
Sep 30 2023	n/a	n/a	-CN¥451m
Jun 30 2023	n/a	n/a	-CN¥440m
Mar 31 2023	n/a	n/a	-CN¥424m
Dec 31 2022	CN¥6m	CN¥1m	-CN¥407m
Sep 30 2022	n/a	n/a	-CN¥666m
Jun 30 2022	n/a	n/a	-CN¥925m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥5m	CN¥1m	-CN¥2b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥364m
Dec 31 2020	CN¥51m	CN¥1m	-CN¥317m
Dec 31 2019	CN¥14m	CN¥823k	-CN¥395m

Rémunération vs marché: La rémunération totale de Xueming ($USD 778.52K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 235.43K ).

Rémunération et revenus: La rémunération de Xueming a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Xueming Qian (55 yo)

12yrs

Titularisation

CN¥5,562,000

Compensation

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Xueming Qian	CEO & Executive Chairman	no data	CN¥5.56m	12.66% CN¥ 68.5m
Xiaolu Weng	Executive VP & CFO	2.8yrs	CN¥8.32m	pas de données
Christopher Hwang	Executive VP of Process Development & CTO	5.7yrs	pas de données	pas de données
Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	2.6yrs	pas de données	pas de données
Yi Gu	Senior VP & Head of Research	5.7yrs	pas de données	pas de données
Charlie Qi	Senior Vice President of Global Clinical Development	1.7yrs	pas de données	pas de données
Xichen Zhang	Senior Vice President of Manufacturing & Quality	2.8yrs	pas de données	pas de données
Wen-I Chang	Senior Vice President of Oncology Franchise Strategy	2.5yrs	pas de données	pas de données
Caroline Germa	Executive VP of Global Medicine Development & Chief Medical Officer	2.2yrs	pas de données	pas de données
Kwan Wai Leung	Company Secretary	3.3yrs	pas de données	pas de données

2.8yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 6628 est considérée comme expérimentée (ancienneté moyenne 2.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Xueming Qian	CEO & Executive Chairman	12yrs	CN¥5.56m	12.66% CN¥ 68.5m
Briggs W. Morrison	Chairman of Scientific Advisory Board	no data	pas de données	pas de données
Pasi Antero Janne	Member of Scientific Advisory Board	no data	pas de données	pas de données
Kumar Srinivasan	Independent Non-Executive Director	1.8yrs	CN¥226.00k	pas de données
Ling Su	Member of Scientific Advisory Board	no data	pas de données	pas de données
Wei Chen	Independent Non-Executive Director	1.2yrs	CN¥72.00k	pas de données
Susan M. Jerian	Member of Scientific Advisory Board	no data	pas de données	pas de données
Li Xu	Member of Scientific Advisory Board	3.7yrs	pas de données	0.18% CN¥ 961.3k
Jiasong Tang	Independent Non-Executive Director	3.1yrs	CN¥219.00k	pas de données
Zhihua Zhang	Independent Non-Executive Director	3.1yrs	CN¥219.00k	pas de données

3.1yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 6628 sont considérés comme expérimentés (ancienneté moyenne 3 ans).

Transcenta Holding Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Transcenta Holding Limited Announces Board and Nomination Changes

Recent updates

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

Transcenta Holding Limited to Report First Half, 2024 Results on Aug 28, 2024

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Consensus EPS estimates fall by 36%

Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.

Less than half of directors are independent

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction